Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify brentuximab vedotin drug-drug interactions in
patients with CD30-positive cancers and to determine the main route of excretion. The study
will also assess blood drug levels in patients with renal or hepatic impairment (special
populations).